ARTICLE | Clinical News

Aranesp darbepoetin alfa: Interim Phase IIIb data

June 12, 2006 7:00 AM UTC

Interim data from an open-label, 16-week, European Phase IIIb trial in 196 evaluable patients showed that 94% of those receiving 500 µg Aranesp every 3 weeks in combination with IV iron achieved targe...